9-oxo-9H-fluorene-3-carboxylic acid | 38570-92-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: 9-oxo-9H-fluorene-3-carboxylic acid
• 英文别名: 9-Fluorenone-3-carboxylic acid；9-oxofluorene-3-carboxylic acid
• CAS: 38570-92-2
• 化学式: C₁₄H₈O₃
• 分子量: 224.216
• InChiKey: GDKWDTSCNHRTOI-UHFFFAOYSA-N

物化性质

• 熔点：
  285-286 °C(Solv: acetic acid (64-19-7))
• 沸点：
  466.9±24.0 °C(Predicted)
• 密度：
  1.424±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  9-oxo-9H-fluorene-3-carboxylic acid 在 氢氧化钾 作用下， 生成 联苯-2,3’-二羧酸
  参考文献：
  名称：

  Sieglitz; Schatzkes, Chemische Berichte, 1921, vol. 54, p. 2077

  摘要：

  DOI：
• 作为产物：
  描述：

  2,5-dimethylphenylmagnesium bromide 在 potassium permanganate 、 PPA 、 乙醚 、 sulfur 作用下， 生成 9-oxo-9H-fluorene-3-carboxylic acid
  参考文献：
  名称：

  A New Route to 3- and 2,6-Substituted Fluorenes²

  摘要：

  DOI：

  10.1021/jo01102a029

文献信息

• Electronic effects on the substitution reactions of benzhydrols and fluorenyl alcohols. Determination of mechanism and effects of antiaromaticity
  作者：Stephen R. D. George、Timothy E. Elton、Jason B. Harper

  DOI：10.1039/c5ob01637a

  日期：——

  Fusion of benzhydrols to give fluorenols is found to not affect the electronic susceptibility of substitution reactions suggesting the antiaromaticity of the intermediate serves simply to slow the process.

  将联苯酚融合成氟酚，发现它并不影响取代反应的电子敏感性，这表明中间体的反芳香性仅用于减慢过程。
• Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same
  申请人：Baroni Marco

  公开号：US20050014795A1

  公开（公告）日：2005-01-20

  The present invention relates to compounds of formula (I): in which X represents N or CH; R 1 represents a hydrogen or halogen atom or a CF 3 group; n is an integer from 1 to 5; A represents a partially saturated carbonaceous bi- or tricycle; it also relates to their salts, solvates, N-oxides, the pharmaceutical compositions containing them, a method for their preparation and synthesis intermediates in this method.

  这项发明涉及以下式(I)的化合物： 其中 X代表N或CH；R1代表氢原子或卤素原子或CF3基团；n是1到5之间的整数；A代表部分饱和的碳质双环或三环；还涉及它们的盐、溶剂合物、N-氧化物、含有它们的药物组合物、其制备方法以及该方法中的合成中间体。
• Synthesis and structure–activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT2B and 5-HT7 receptor antagonists
  作者：Ayako Moritomo、Hiroyoshi Yamada、Toshihiro Watanabe、Hirotsune Itahana、Shinobu Akuzawa、Minoru Okada、Mitsuaki Ohta

  DOI：10.1016/j.bmc.2013.10.010

  日期：2013.12

  To identify potent dual 5-HT2B and 5-HT7 receptor antagonists, we synthesized a series of novel carbonyl guanidine derivatives and examined their structure–activity relationships. Among these compounds, N-(9-hydroxy-9H-fluorene-2-carbonyl)guanidine (10) had a good in vitro profile, that is, potent affinity for human 5-HT2B and 5-HT7 receptor subtypes (Ki = 1.8 nM and Ki = 17.6 nM, respectively) and

  为了鉴定有效的双重5-HT 2B和5-HT 7受体拮抗剂，我们合成了一系列新型羰基胍衍生物，并研究了它们的结构-活性关系。在这些化合物中，N-（9-羟基-9 H-芴-2-羰基）胍（10）具有良好的体外特性，即对人5-HT 2B和5-HT 7受体亚型的有效亲和力（ķ我 = 1.8纳米和ķ我 = 17.6纳米，）和高选择性超过5-HT 2A，5-HT 2C，α 1，d 2和M 1受体。当口服时，化合物10还对豚鼠的5-HT诱导的硬脑膜蛋白渗出具有抑制作用。
• Aralkyltetrahydropyridines, Their Preparation and Pharmaceutical Compositions Containing Them
  申请人：BARONI Marco

  公开号：US20080097117A1

  公开（公告）日：2008-04-24

  The present invention relates to compounds of formula (I): in which X represents N or CH; R 1 represents a hydrogen or halogen atom or a CF 3 group; n is an integer from 1 to 5; A represents a partially saturated carbonaceous bi- or tricycle; it also relates to their salts, solvates, N-oxides, the pharmaceutical compositions containing them, a method for their preparation and synthesis intermediates in this method.

  本发明涉及公式（I）的化合物：其中X代表N或CH；R1代表氢或卤素原子或CF3基团；n为1至5的整数；A代表部分饱和的碳质二元或三元环；还涉及它们的盐、溶剂化物、N-氧化物、含有它们的药物组合物、它们的制备方法和合成中间体。
• 11BETA-HSD1 ACTIVE COMPOUNDS
  申请人：Ebdrup Soren

  公开号：US20100056600A1

  公开（公告）日：2010-03-04

  A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g. the metabolic syndrome.

  本文描述了一类通式为(I)的新化合物，它们在治疗中的应用，包括含有这些化合物的药物组合物，以及它们在制造药物中的应用。这些化合物调节11β-羟基类固醇脱氢酶1型（11βHSD1）的活性，因此在治疗调节该酶活性有益的疾病，如代谢综合征中有用。